Stay updated with breaking news from நாள்பட்ட. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Let s Talk about Long-COVID (Chronic COVID Syndrome) insights from industryGermano TarantinoScientific DirectorPharmaNutra S.p.A In this interview, Germano Tarantino, the Scientific Director at PharmaNutra S.p.A, talks to NewsMed about long-COVID (also known as chronic COVID syndrome). To begin, can you tell us a bit about chronic COVID syndrome (also known as Long-COVID) and some of its symptoms? Long-COVID is a syndrome characterized by long-term SARS-CoV-2 infection symptoms persistent at least 4 weeks from the onset of symptoms. In fact, even if most people affected by COVID-19 recover completely within a few weeks, some other, continue to experience symptoms after many weeks or months ....
New service enables patients to recover safely at home, avoid hospitalization A new service piloted at Penn Medicine allowed a proportion of patients to avoid hospitalization by providing them with greater support after visiting the emergency department. The vast majority of the patients enrolled in the service - nearly 9 out of 10 - did not need to return to the hospital for care in the month that followed their initial visit. The study was published in Healthcare. The culture is shifting where we realize that hospitalization is not always the best option for patients - particularly patients with chronic illness. We need to find better ways of helping patients not just get healthy in a hospital, but stay healthy at home - whenever they are ready to be there. ....
Scientists at the Walter Reed Army Institute for Research demonstrated that biomarkers associated with traumatic brain injury were elevated among law enforcement and military personnel, particularly in active duty participants with longer duration of service. ....
Why analysts continue to impose their faith in this midcap pharma stock Synopsis Sanofi India’s management has adopted cost control measures and has lowered promotional spends, which was visible in 2020. Its digital push, recent underperformance and the resultant lower valuation are the other factors that have made the company a favourite of analysts. Chronic therapeutic treatments contribute around 63% of Sanofi India’s domestic sales and the same is now under several restrictions due to the Covid-19 related disturbances. The company’s growth opportunities should improve once the situation stabilises and patients start coming back to the hospitals for treatment of other diseases. Despite short-term challenges, Sanofi continues to do well and was able to beat the street expectations with its ....
Sanofi s valuations are attractive: Why it is stock pick of week Synopsis Despite being a mid-cap pharma company, analysts continue to impose their faith in Sanofi India due to its long term growth outlook. Chronic therapeutic treatments contribute around 63% of Sanofi India’s domestic sales and the same is now under several restrictions due to the Covid-19 related disturbances. The company’s growth opportunities should improve once the situation stabilises and patients start coming back to the hospitals for treatment of other diseases. Despite short-term challenges, Sanofi continues to do well and was able to beat the street expectations with its ....